For biotechnology companies eyeing Europe, the prize is substantial, and so is the difficulty. Reaching one of the world’s largest healthcare markets takes more than promising science. Companies must work through sophisticated regulatory frameworks, raise capital, form the right partnerships and decide where to base their European operations.
Those challenges, along with the opportunities that come with them, were the focus of a session titled “Where Regulation Meets Opportunity: EMA and the Dutch Investment Climate,” held on 16 July at BIO Asia–Taiwan 2026 in Taipei.
Co-organised by the Netherlands Foreign Investment Agency (NFIA), the session gathered investment and regulatory experts to examine a question of growing importance for Asia’s biotech sector: how the Netherlands can act as a strategic entry point into the European life sciences market, and how earlier contact with regulators can help innovative medicines and technologies move more smoothly towards development and commercialisation.
The Netherlands makes its case as a life sciences gateway
Opening the session, Lauren Liebe, Business Analyst for Life Science and Health at the Netherlands Foreign Investment Agency, introduced the scope of the Dutch life sciences and health ecosystem.
For international companies, the Netherlands offers more than a convenient location. Its appeal rests on the closeness of scientific institutions, healthcare expertise, established pharmaceutical and biotechnology operations, specialised talent and access to the broader European market.
The presence of the European Medicines Agency in Amsterdam has added a further dimension, reinforcing the country’s position at the meeting point of science, regulation and commercial opportunity.
For Asian biotech firms weighing international expansion, this raises a key strategic question. Rather than treating Europe merely as an export destination, should companies begin shaping their European regulatory, clinical and commercial strategies far earlier in their development? The discussion in Taipei suggested the answer increasingly points towards earlier engagement.
Capital matters, but so does the investment environment
The session also turned to one of the most decisive factors in international expansion: access to capital and the wider financial climate in which companies operate.
Marielle Lagers, Executive Director of the Netherlands Foreign Investment Agency in Taiwan, joined by Renee Yeh, Senior Associate at Briddge, drew attention to the role of Dutch incentives and taxation frameworks in supporting companies considering European investment.
For biotechnology businesses, though, investment decisions rarely hinge on incentives alone. The real calculation takes in the whole operating environment, from talent and research partnerships to regulatory access, financing options and the capacity to scale internationally.
This is where the Dutch offer becomes especially relevant. By pairing a mature life sciences ecosystem with connectivity to the wider European market, the Netherlands is presenting itself not simply as a place to open an office, but as a platform from which companies can build their European growth strategies.
Regulation is becoming a strategic capability
The heart of the session was a detailed discussion of European regulation led by Sebastian Asprella, Programme Lead for EU Competitiveness, Regulatory Science and Innovation at the European Medicines Agency, and Thomas Ballotti, Scientific Officer at EMA.
Their talk, “Demystifying EU Regulations,” concentrated on the regulatory support tools available to developers of innovative medicines and technologies.
For emerging biotech companies, especially those entering Europe for the first time, regulation can often feel like a hurdle that appears near the end of product development. The more important message from the discussion was that regulatory strategy should instead be treated as a built-in part of innovation.
Early scientific and regulatory engagement can help developers grasp evidence expectations, spot potential gaps in development programmes and make better-informed decisions before significant capital and time have been spent.
This matters all the more as biotechnology moves into increasingly complex scientific territory. Advanced therapies, precision medicines and emerging technology platforms do not always fit neatly within traditional development models. The ability of innovators and regulators to engage early therefore becomes ever more important in translating breakthrough science into products that can ultimately reach patients.
Europe’s opportunity is also Asia’s opportunity
The session’s significance reached well beyond the Netherlands.
Across Asia, biotechnology ecosystems are producing increasingly sophisticated technologies and globally ambitious companies. Taiwan in particular is building its capabilities across drug development, precision medicine, advanced therapies and biomanufacturing.
As these companies look abroad, Europe represents both a major market and an important development ecosystem. Yet successful entry will depend on recognising that regulation, investment and market access cannot be tackled in isolation.
The Netherlands is making a persuasive case for being the place where these threads can come together. With the EMA based in Amsterdam and a wider ecosystem built to attract international life sciences investment, the country holds a distinctive spot in Europe’s biotechnology landscape. For Asian companies, that closeness, both institutional and commercial, could grow more valuable as they develop global strategies.
From regulatory compliance to competitive advantage
Perhaps the most important takeaway was a shift in perspective.
Regulation is often framed as something innovation has to overcome. But for companies in highly complex, capital-intensive industries, regulatory understanding can itself become a competitive advantage.
Companies that engage earlier, design development programmes with regulatory expectations in mind and root themselves within ecosystems capable of supporting international expansion may be better placed to move from promising science to globally viable products.
The session at BIO Asia–Taiwan 2026 captured a broader shift underway across the global biotechnology industry. The next generation of successful biotech companies will not compete on science alone. They will compete on how well they connect science with regulation, capital and market access.
And at exactly that intersection, the Netherlands is positioning itself as an increasingly important gateway between Asia’s biotechnology ambitions and Europe’s healthcare market.
